Barnes et al. [105] demonstrated that estrogen receptor- (ER-) positive cancer cells are sensitized to cisplatin by treatment with estrogen, which could shield cisplatin-DNA adducts from NER through overexpression of the high-mobility group box 1 (HMGB1) protein. Here, ESR1 is linked to cancer.